Study to Evaluate the Efficacy, Safety, Tolerability and Immunogenicity of 100µg NIC002 Vaccine in Cigarette Smokers Who Are Motivated to Quit Smoking.

PHASE2CompletedINTERVENTIONAL

Enrollment

200

Participants

Timeline

Start Date

August 31, 2008

Primary Completion Date

October 31, 2009

Study Completion Date

October 31, 2009

Conditions

Smokers

Interventions

BIOLOGICAL

NIC002

BIOLOGICAL

Placebo

Trial Locations (2)

Novartis Investigative Site, Mainz

Novartis Investigator Site, Neuss